ZA932415B - Compounds for the treatment of neurodegenerative disorders - Google Patents

Compounds for the treatment of neurodegenerative disorders

Info

Publication number
ZA932415B
ZA932415B ZA932415A ZA932415A ZA932415B ZA 932415 B ZA932415 B ZA 932415B ZA 932415 A ZA932415 A ZA 932415A ZA 932415 A ZA932415 A ZA 932415A ZA 932415 B ZA932415 B ZA 932415B
Authority
ZA
South Africa
Prior art keywords
treatment
neurodegenerative disorders
compounds
pyridineethanamine
alpha
Prior art date
Application number
ZA932415A
Other languages
English (en)
Inventor
Robert John Murray
Ronald Conrad Griffith
Michael Balestra
Original Assignee
Fisons Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Fisons Corp filed Critical Fisons Corp
Publication of ZA932415B publication Critical patent/ZA932415B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
ZA932415A 1992-04-03 1993-04-02 Compounds for the treatment of neurodegenerative disorders ZA932415B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
ZA932415B true ZA932415B (en) 1993-10-22

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932415A ZA932415B (en) 1992-04-03 1993-04-02 Compounds for the treatment of neurodegenerative disorders

Country Status (29)

Country Link
EP (1) EP0633879B1 (ru)
JP (2) JP3120810B2 (ru)
KR (1) KR100259567B1 (ru)
CN (1) CN1044367C (ru)
AT (1) ATE163925T1 (ru)
AU (2) AU3897693A (ru)
CA (1) CA2133427C (ru)
CZ (1) CZ288519B6 (ru)
DE (1) DE69317411T2 (ru)
DK (1) DK0633879T3 (ru)
DZ (1) DZ1677A1 (ru)
ES (1) ES2115055T3 (ru)
FI (1) FI105025B (ru)
HK (1) HK1009331A1 (ru)
HU (1) HU211529A9 (ru)
IL (1) IL105276A (ru)
MA (1) MA22866A1 (ru)
MX (1) MX9301935A (ru)
MY (1) MY110149A (ru)
NO (1) NO302170B1 (ru)
NZ (1) NZ251384A (ru)
PL (1) PL180014B1 (ru)
RU (1) RU2128650C1 (ru)
SG (1) SG47948A1 (ru)
SK (1) SK281258B6 (ru)
TW (1) TW282455B (ru)
UA (1) UA29437C2 (ru)
WO (1) WO1993020052A1 (ru)
ZA (1) ZA932415B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
EP0648489A1 (en) * 1988-08-12 1995-04-19 Fisons Corporation Arylalkylamides having neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
SG171928A1 (en) 2008-12-24 2011-07-28 Astrazeneca Ab Ethanamine compounds and their use for treating depression
JP2015501652A (ja) 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Gabr−a2診断
PT3066091T (pt) 2013-11-05 2019-07-11 Astrazeneca Ab Pro-farmacos de antagonista de nmda
US20230190719A1 (en) * 2020-06-23 2023-06-22 Biohaven Therapeutics Ltd. Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648489A1 (en) * 1988-08-12 1995-04-19 Fisons Corporation Arylalkylamides having neuroprotective properties

Also Published As

Publication number Publication date
EP0633879B1 (en) 1998-03-11
TW282455B (ru) 1996-08-01
AU3897693A (en) 1993-11-08
DK0633879T3 (da) 1998-09-28
SG47948A1 (en) 1998-04-17
EP0633879A1 (en) 1995-01-18
CN1081669A (zh) 1994-02-09
NO302170B1 (no) 1998-02-02
NZ251384A (en) 1996-10-28
SK117794A3 (en) 1995-05-10
MA22866A1 (fr) 1993-12-31
CZ240994A3 (en) 1995-12-13
CA2133427C (en) 2003-06-10
MX9301935A (es) 1994-08-31
SK281258B6 (sk) 2001-01-18
DE69317411T2 (de) 1998-07-30
CN1044367C (zh) 1999-07-28
NO943645L (no) 1994-11-16
IL105276A0 (en) 1993-08-18
IL105276A (en) 1997-06-10
HU211529A9 (en) 1995-11-28
NO943645D0 (no) 1994-09-30
PL180014B1 (pl) 2000-11-30
CA2133427A1 (en) 1993-10-14
FI944546A (fi) 1994-09-30
FI944546A0 (fi) 1994-09-30
AU7545696A (en) 1997-02-13
RU2128650C1 (ru) 1999-04-10
JP2000319259A (ja) 2000-11-21
CZ288519B6 (cs) 2001-07-11
DE69317411D1 (de) 1998-04-16
AU705419B2 (en) 1999-05-20
JPH07505385A (ja) 1995-06-15
WO1993020052A1 (en) 1993-10-14
HK1009331A1 (en) 1999-05-28
UA29437C2 (ru) 2000-11-15
DZ1677A1 (fr) 2002-02-17
MY110149A (en) 1998-02-28
KR100259567B1 (ko) 2000-07-01
JP3120810B2 (ja) 2000-12-25
FI105025B (fi) 2000-05-31
ES2115055T3 (es) 1998-06-16
ATE163925T1 (de) 1998-03-15
RU94042465A (ru) 1996-07-20

Similar Documents

Publication Publication Date Title
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
AU610036B2 (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis inflammation and as immunosuppressants
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
ZA928158B (en) Cytotoxic bicyclo[7.3.1]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof.
SG47948A1 (en) Compounds for the treatment of neurodegenerative disorders
EP0626162A3 (de) Krankenbett.
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
CA2135710A1 (en) Melatonin derivatives for use in treating desynchronization disorders
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
HRP931016A2 (en) Thienothiazin derivatives, process for the preparation and application thereof
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
ZA949347B (en) 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical agents containing these compounds and process for their production.
EP0583136A3 (en) Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders
AU3084992A (en) 1,4-dihydropyridines for use in the treatment of dermatosis
AU4825993A (en) New compounds for use in the treatment of cancer
GB2270313B (en) 1,3,4-Benzotriazepin-5 (4H)-one derivatives and process for the preparation thereof
GR3036226T3 (en) 6-methoxy-1h-benzotriazole-5-carboxamide derivatives, process for producing the same, and medicinal composition containing the same
AU7183298A (en) Melatonin derivatives for use in treating desynchronization disorders
ZA934785B (en) 17-halogeno-4-azaandrostene derivatives and process for the preparation thereof.
ES1023651Y (es) "barandilla de cama, perfeccionada"
ZA932062B (en) Indole and indazole derivatives, for the treatment and prophylaxis of cerabral disorders, their preparation and their use
IL100396A0 (en) Medicaments for the treatment of irradiation damages
HUP9603287A3 (en) Pharmaceutical composition, use thereof and process for producing the active component